Related Experiment Video

Updated: Jan 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer

Andrea Lancia1, Marco Oderda2, Federico Camilli3

  • 1Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2025
PubMed

Insights

Androgen receptor pathway inhibitors (ARPIs) are improving outcomes for prostate cancer (PCa) patients. This review details ARPI indications across all stages of castration-sensitive prostate cancer (CSPC).

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer (PCa) is a leading cancer in men, often diagnosed at advanced stages.
  • Androgen Deprivation Therapy (ADT) is a standard treatment for high-risk, recurrent, or metastatic PCa.
  • Androgen Receptor Pathway Inhibitors (ARPIs) have emerged as crucial additions to ADT, improving outcomes.

Purpose of the Study:

  • To provide a comprehensive overview of current indications for ARPIs in Castration-Sensitive Prostate Cancer (CSPC).
  • To discuss the evolving role of ARPIs across different stages of CSPC, including early-stage and treatment-naive patients.

Main Methods:

  • Literature review of clinical trials and guidelines.
  • Analysis of data on ARPI efficacy and safety in CSPC.
  • Synthesis of evidence regarding treatment intensification with ARPIs.

Main Results:

  • ARPIs demonstrate significant benefits when added to ADT in metastatic CSPC.
  • Evidence supports earlier use of ARPIs, even in patients not previously treated with ADT.
  • Treatment intensification with ARPIs is indicated for patients with high-risk features.

Conclusions:

  • ARPIs represent a significant advancement in CSPC management.
  • The review highlights the expanding indications for ARPIs across the spectrum of CSPC.
  • Optimizing ARPI use in CSPC is crucial for improving patient outcomes.
Keywords:
androgen receptor pathway inhibitormetastasesprostate cancerradiotherapysurgery

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K
Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K